ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

House Subcommittee Passes Bush Request for NIH, NCI Budgets.

June 9, 2006

House Committee Asks Varmus About Impact of Clinical Center construction On NIH Programs

April 26, 1996

Support Available For Studies Abroad

August 12, 1983

NCI to Establish Three Grants Programs Supporting Clinical Cancer Research

February 18, 1994

In Brief: Clinton Backs Ban On Human Cloning; Wisconsin Selects Niederhuber As Director

June 13, 1997

New Trial For Metastatic Colorectal Cancer Testing Vaccine-Chemotherapy Combination

March 29, 2002